Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Alnylam Pharmaceuticals (ALNY) PT Lowered to $175 at BMO Capital
February 11, 2022 7:21 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $175.00 (from $180.00) while maintaining a Market Perform rating.
The analyst commented, "Solid 4Q product revenue was preannounced as key commercial products (Onpattro/Givlaari/Oxlumo) continue good momentum with increased... More
Alnylam Pharma (ALNY) Misses Q4 EPS by 13c
February 10, 2022 8:07 AM ESTAlnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.69), $0.13 worse than the analyst estimate of ($1.56). Revenue for the quarter came in at $258.5 million versus the consensus estimate of $231.44 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
... More